Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Stanford University
Kivu Bioscience Inc.
ViroMissile, Inc.
Pfizer
Pfizer
Pfizer
Tizona Therapeutics, Inc
ALX Oncology Inc.
Clasp Therapeutics, Inc.
Eli Lilly and Company
USWM, LLC (dba US WorldMeds)
MacroGenics
Adaptimmune
Solve Therapeutics
Eli Lilly and Company
OncoNano Medicine, Inc.
GlaxoSmithKline
Memorial Sloan Kettering Cancer Center
University of Chicago
AccSalus Biosciences, Inc.
Therorna
Incyte Corporation
M.D. Anderson Cancer Center
Sichuan Baili Pharmaceutical Co., Ltd.
Nurix Therapeutics, Inc.
Memgen, Inc.
Incyte Corporation
University of California, San Diego
AbbVie
Scholar Rock, Inc.
Regeneron Pharmaceuticals
Carisma Therapeutics Inc
Symphogen A/S
Acepodia Biotech, Inc.
Taiho Pharmaceutical Co., Ltd.
Pfizer
Pfizer
University of California, San Francisco
Yale University
Adaptimmune
Ipsen
Rutgers, The State University of New Jersey
Providence Health & Services
Seagen Inc.
H. Lee Moffitt Cancer Center and Research Institute
Herlev Hospital
Quadriga Biosciences, Inc.
Wellmarker Bio
Pfizer